J. Mellors

J. Mellors, D. Porter, M. Horowitz, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Progress in Basic and Clinical Research on HIV Resistance: Report on the XVIII International HIV Drug Resistance Workshop

D. Richman, B. Larder, J. Mellors, 2009, Antiviral therapy.

Panel on Clinical Practices for Treatment of HIV Infection

John W. Mellors, Martin Delaney, Robert T. Schooley, 2000 .

Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000

J. J. Henning, John G. Bartlett, Martin Delaney, 1998, HIV clinical trials.

A Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1–Infected Adults With Virologic Suppression on a Protease Inhibitor–Containing Regimen

S. Hammer, J. Mellors, K. Squires, 2010 .

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.

J. Mellors, J. Coffin, S. Swindells, 2009, The Journal of infectious diseases.

Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial.

M. Hughes, R. Gross, J. Mellors, 2019, The Lancet. Digital health.

Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.

J. Mellors, K. Shutt, R. Wood, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Base Component of 3′-Azido-2′,3′-Dideoxynucleosides Influences Resistance Mutations Selected in HIV-1 Reverse Transcriptase

J. Mellors, R. Schinazi, N. Sluis-Cremer, 2011, Antimicrobial Agents and Chemotherapy.

Anti-Human Immunodeficiency Virus Activity, Cross-Resistance, Cytotoxicity, and Intracellular Pharmacology of the 3′-Azido-2′,3′-Dideoxypurine Nucleosides

J. Mellors, R. Schinazi, N. Sluis-Cremer, 2009, Antimicrobial Agents and Chemotherapy.

Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir

J. Mellors, H. Bazmi, D. Koontz, 2010, Antiviral therapy.

PAPNC, a novel method to calculate nucleotide diversity from large scale next generation sequencing data.

J. Mellors, J. Coffin, F. Maldarelli, 2014, Journal of virological methods.

Associations of HIV persistence, cigarette smoking, inflammation, and pulmonary dysfunction in people with HIV on antiretroviral therapy

J. Mellors, C. Rinaldo, P. Tien, 2022, Medicine.

Potent and broad neutralization of SARS-CoV-2 variants of concern (VOCs) including omicron sub-lineages BA.1 and BA.2 by biparatopic human VH domains

Michele D. Sobolewski, M. H. Cheng, I. Bahar, 2022, iScience.

Early Emergence and Long-Term Persistence of HIV-Infected T-Cell Clones in Children

S. Hughes, J. Mellors, J. Coffin, 2021, mBio.

Early Emergence and Long-Term Persistence of HIV-Infected T Cell Clones in Children

S. Hughes, J. Mellors, J. Coffin, 2020, bioRxiv.

Use of recombinant retroviruses to characterize the activity of antiretroviral compounds

J. Mellors, C. J. Nelson, R. Stair, 1991, Journal of virology.

Anti-Human Immunodeﬁciency Virus Type 1 (HIV-1) CD8 1 T-Lymphocyte Reactivity during Combination Antiretroviral Therapy in HIV-1-Infected Patients with Advanced Immunodeﬁciency

J. Margolick, J. Mellors, C. Rinaldo, 2000 .

Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors

Michele D. Sobolewski, Wei-Shau Hu, S. Hughes, 2019, Proceedings of the National Academy of Sciences.

Potential Impact and Cost-Effectiveness of Condomless-Sex–Concentrated PrEP in KwaZulu-Natal Accounting for Drug Resistance

A. Phillips, J. Mellors, P. Revill, 2019, The Journal of infectious diseases.

Pretreatment HIV-1 drug resistance is strongly associated with virologic failure in HIV-infected patients receiving partly active antiretroviral regimens.

J. Mellors, U. Parikh, 2012, Future microbiology.

Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low‐ and Middle‐Income Countries

J. Mellors, J. Fitzgibbon, C. Godfrey, 2017, The Journal of infectious diseases.

SARS-CoV-2 Viremia is Associated with COVID-19 Severity and Predicts Clinical Outcomes.

Simon C Watkins, Janet S. Lee, J. Mellors, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Pregnancy in Sub-Saharan Africa: A 6-Country Retrospective Cohort Analysis

J. Stringer, L. Myer, A. Kengne, 2022, Clinical Infectious Diseases.

Mechanisms by Which the G333D Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Facilitates Dual Resistance to Zidovudine and Lamivudine

J. Mellors, N. Sluis-Cremer, J. Radzio, 2007, Antimicrobial Agents and Chemotherapy.

Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice

D. Dimitrov, J. Mellors, A. Drelich, 2020, Vaccine.

IgG response to SARS-CoV-2 and seasonal coronaviruses contributes to complement overactivation in severe COVID-19 patients.

J. Mellors, B. Methé, U. Braga-Neto, 2022, The Journal of infectious diseases.

Contribution of Coronavirus-Specific Immunoglobulin G Responses to Complement Overactivation in Patients with Severe Coronavirus Disease 2019

J. Mellors, U. Braga-Neto, A. Naqvi, 2022, The Journal of Infectious Diseases.

Human Antibody Domains and Fragments Targeting Neutrophil Elastase as Candidate Therapeutics for Cancer and Inflammation-Related Diseases

D. Dimitrov, J. Mellors, S. Shapiro, 2021, International journal of molecular sciences.

Transcriptional Changes in CD8+ T Cells During Antiretroviral Therapy Intensified With Raltegravir

Xu G. Yu, J. Mellors, R. Bosch, 2015, Open forum infectious diseases.

Transcriptional Changes in CD 8 + T Cells During Antiretroviral Therapy Intensi fi ed With Raltegravir

Xu G. Yu, J. Mellors, R. Bosch, 2015 .

Divergent trajectories of antiviral memory after SARS-CoV-2 infection

P. Klenerman, T. Wrin, C. Petropoulos, 2021, Nature Communications.

Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients: An Observational, Prospective Cohort Study Interim Analysis

J. Luketich, J. Mellors, D. Angus, 2021, medRxiv.

Scaling Up Covid-19 Vaccination in Africa - Lessons from the HIV Pandemic.

J. Nachega, J. Mellors, L. Mofenson, 2021, The New England journal of medicine.

Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine

M. Hughes, J. Mellors, J. Coffin, 2011, Proceedings of the National Academy of Sciences.

Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study

Michele D. Sobolewski, Janet S. Lee, J. Mellors, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019

J. Mellors, G. Haidar, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Amplifying and quantifying HIV-1 RNA in HIV infected individuals with viral loads below the limit of detection by standard clinical assays.

J. Mellors, J. Coffin, F. Maldarelli, 2011, Journal of visualized experiments : JoVE.

Effects of Speciﬁc Zidovudine Resistance Mutations and Substrate Structure on Nucleotide-Dependent Primer Unblocking by Human Immunodeﬁciency Virus Type 1 Reverse Transcriptase

J. Mellors, A. So, W. Scott, 2002 .

CD8 1 T-Cell Gamma Interferon Production Speciﬁc for Human Immunodeﬁciency Virus Type 1 (HIV-1) in HIV-1-Infected Subjects

J. Mellors, C. Rinaldo, Xiao-li Huang, 2000 .

Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models

R. Glaubius, K. Lythgoe, J. Eaton, 2013, AIDS.

A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.

J. Mellors, J. Currier, A. Landay, 2012, The Journal of infectious diseases.

Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy.

J. Mellors, F. Maldarelli, D. McMahon, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Substrate mimicry: HIV-1 reverse transcriptase recognizes 6-modified-3′-azido-2′,3′-dideoxyguanosine-5′-triphosphates as adenosine analogs

Richard A. Stanton, J. Nettles, J. Mellors, 2011, Nucleic acids research.

Madurahydroxylactone Derivatives as Dual Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and RNase H

Y. Pommier, J. Mellors, S. L. Le Grice, 2007, Antimicrobial Agents and Chemotherapy.

The transformation of HIV therapy: One pill once a day

J. Mellors, Madhuchanda Choudhary, 2022, Antiviral therapy.

Special Collection: A pioneer in antiviral drug discovery and development: Commemorating John Martin-Original Article

J. Mellors, Madhuchanda Choudhary, 2022 .

The 3′-Azido Group Is Not the Primary Determinant of 3′-Azido-3′-deoxythymidine (AZT) Responsible for the Excision Phenotype of AZT-resistant HIV-1*

J. Mellors, R. Schinazi, N. Sluis-Cremer, 2005, Journal of Biological Chemistry.

Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T).

J. Mellors, R. E. Anderson, S. Riddler, 1995, Antiviral research.

Sanctuary growth of human immunodeficiency virus in the presence of 3'-azido-3'-deoxythymidine

J. Mellors, R. Strair, D. Medina, 1995, Journal of virology.

Reduction of the HIV-1 reservoir in T cells from persons with HIV-1 on suppressive antiretroviral therapy using expanded natural killer cells ex vivo

Michele D. Sobolewski, J. Karn, J. Mellors, 2022, bioRxiv.

Frequent Emergence of N 348 I in HIV-1 Subtype C Reverse Transcriptase with Failure of Initial Therapy Reduces Susceptibility to Reverse-Transcriptase Inhibitors

J. Mellors, K. Shutt, R. Wood, 2012 .

The Base Component of 3 (cid:1) -Azido-2 (cid:1) ,3 (cid:1) -Dideoxynucleosides Inﬂuences Resistance Mutations Selected in HIV-1 Reverse Transcriptase (cid:1)

J. Mellors, R. Schinazi, N. Sluis-Cremer, 2011 .

A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.

S. Hammer, J. Mellors, K. Squires, 2010, HIV clinical trials.

Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro

J. Mellors, D. Medina, G. Hsiung, 1992, Antimicrobial Agents and Chemotherapy.

The COVID misinfodemic: not new, never more lethal

J. Mellors, C. Apetrei, I. Pandrea, 2022, Trends in Microbiology.

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206

J. Mellors, D. Kitch, J. Aberg, 2010, AIDS.

Achieving Viral Suppression in 90% of People Living With Human Immunodeficiency Virus on Antiretroviral Therapy in Low- and Middle-Income Countries: Progress, Challenges, and Opportunities

J. Nachega, J. Mellors, L. Mofenson, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV-1 drug resistance resulting from antiretroviral therapy far exceeds that from pre-exposure prophylaxis.

J. Mellors, U. Parikh, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV mediates a productive infection of the brain.

C A Wiley, E. Masliah, J. Mellors, 1999, AIDS.

Science Magazine

J. Mellors, K. McCormick, J. Jacobs, 2006 .

Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA in Blood of Patients With Coronavirus Disease 2019 (COVID-19): What Does It Mean?

J. Mellors, J. Jacobs, 2020, Clinical Infectious Diseases.

Detection of SARS-CoV-2 RNA in Blood of Patients with COVID-19: What Does It Mean?

J. Mellors, J. Jacobs, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Multiple Sources of Contamination in Samples from Patients Reported to Have XMRV Infection

S. Hughes, J. Mellors, J. Coffin, 2012, PloS one.

Prevalence of XMRV Nucleic Acid and Antibody in HIV-1-Infected Men and in Men at Risk for HIV-1 Infection

Steven Wolinsky, J. Mellors, J. Coffin, 2011, Advances in virology.

Nucleic Acid, Antibody, and Virus Culture Methods to Detect Xenotropic MLV-Related Virus in Human Blood Samples

W. Linehan, C. Vocke, V. Pathak, 2011, Advances in virology.

Deciphering the Effects of Injectable Pre-exposure Prophylaxis for Combination Human Immunodeficiency Virus Prevention

R. Glaubius, U. Abbas, J. Mellors, 2016, Open forum infectious diseases.

Antiretroviral therapies in women after single-dose nevirapine exposure.

M. Hughes, R. Schooley, J. Mellors, 2010, The New England journal of medicine.

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study

A. Wensing, D. Kuritzkes, D. Pillay, 2018, The lancet. HIV.

Interleukin-6 expression in primary macrophages infected with human immunodeficiency virus-1 (HIV-1).

B. F. Hall, J. Mellors, C. Ruef, 1991, AIDS research and human retroviruses.

Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.

Ashley J. Mayo, J. Baeten, A. van der Straten, 2021, The lancet. HIV.

Anti-HIV-1 activity of 3'-azido-3'-deoxythymidine (AZT) in primary mononuclear phagocytes.

J. Mellors, J. Rankin, D. Beenhouwer, 1992, Antiviral research.

Discovery of a novel human antibody VH domain with potent activity against mesothelin expressing cancer cells in both CAR T-cell and antibody drug conjugate formats

D. Dimitrov, J. Mellors, R. Ishima, 2022, bioRxiv.

Potent neutralization of SARS-CoV-2 in vitro and in an animal model by a human monoclonal antibody

Lisa E. Gralinski, D. Dimitrov, R. Baric, 2020, bioRxiv.

In Vitro Selection and Analysis of Human Immunodeficiency Virus Type 1 Resistant to Derivatives of β-2′,3′-Didehydro-2′,3′-Dideoxy-5-Fluorocytidine

J. Mellors, R. Schinazi, C. K. Chu, 2005, Antimicrobial Agents and Chemotherapy.

Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS)

D. Angus, J. Luketich, M. Schwartz, 2022, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

Alkylglycerol Prodrugs of Phosphonoformate Are Potent In Vitro Inhibitors of Nucleoside-Resistant Human Immunodeficiency Virus Type 1 and Select for Resistance Mutations That Suppress Zidovudine Resistance

D. Richman, J. Mellors, K. Hostetler, 2001, Antimicrobial Agents and Chemotherapy.

Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level.

J. Mellors, U. Parikh, Douglas C Barnas, 2006, The Journal of infectious diseases.

Ultrasensitive single-genome sequencing: accurate, targeted, next generation sequencing of HIV-1 RNA

J. Mellors, B. Luke, J. Coffin, 2016, Retrovirology.

Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection

Roger Detels, J. Margolick, J. Phair, 1997, Annals of Internal Medicine.

Potent neutralization of SARS-CoV-2 in vitro and in an animal model by a human monoclonal antibody.

Lisa E. Gralinski, D. Dimitrov, R. Baric, 2020, bioRxiv : the preprint server for biology.

Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models

Lisa E. Gralinski, D. Dimitrov, R. Baric, 2020 .

Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma

John W. Mellors, L. Kingsley, J. Mellors, 1996, Science.

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

R F Schinazi, J. Mellors, R. Schinazi, 1993, Antimicrobial Agents and Chemotherapy.

Lamivudine-Resistant Viral Variants Activity against Zidovudine- and DPC 817: a Cytidine Nucleoside Analog with

M. Otto, M. Rayner, J. Mellors, 2014 .

DPC 817: a Cytidine Nucleoside Analog with Activity against Zidovudine- and Lamivudine-Resistant Viral Variants

L. Bacheler, M. Otto, M. Rayner, 2002, Antimicrobial Agents and Chemotherapy.

Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up.

D. Richman, D. Havlir, J. Mellors, 1998, JAMA.

HIV‐1 DNA decay is faster in children who initiate ART shortly after birth than later

J. Mellors, M. Cotton, B. Laughton, 2019, Journal of the International AIDS Society.

High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors

L. Kingsley, J. Mellors, Phalguni Gupta, 1997, Journal of virology.

Assessment of Clinical Outcomes Among Children and Adolescents Hospitalized With COVID-19 in 6 Sub-Saharan African Countries

N. Sewankambo, J. Nachega, J. Mellors, 2022, JAMA pediatrics.

Proceedings of the Frontiers of Retrovirology Conference 2016

R. König, D. Elleder, R. Sachidanandam, 2016, Retrovirology.

Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy.

J. Mellors, Phalguni Gupta, R. Montelaro, 2004, AIDS research and human retroviruses.

Telemedicine and Infectious Diseases Practice: A Leap Forward or a Step Back?

J. Mellors, R. Abdel-Massih, 2019, Open forum infectious diseases.

Ritonavir and saquinavir combination therapy for the treatment of HIV infection.

R Rode, M Salgo, D. Ho, 1999, AIDS.

Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides.

J. Nettles, J. Mellors, R. Schinazi, 2011, European journal of medicinal chemistry.

Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase

J. Mellors, N. Sluis-Cremer, U. Parikh, 2007, AIDS.

Molecular Mechanism by Which the K70E Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Resistance to Nucleoside Reverse Transcriptase Inhibitors

J. Mellors, N. Sluis-Cremer, U. Parikh, 2006, Antimicrobial Agents and Chemotherapy.

The use of β-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection

J. Mellors, D. Margolis, C. Fletcher, 2007, AIDS.

Synthesis and evaluation of 3'-azido-2',3'-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus.

Steven J Coats, J. Mellors, R. Schinazi, 2010, Bioorganic & Medicinal Chemistry Letters.

Safety and pharmacokinetics of 5-chloro-2',3'-dideoxy-3'-fluorouridine (935U83) following oral administration of escalating single doses in human immunodeficiency virus-infected adults

J. Bartlett, J. Mellors, S. Riddler, 1996, Antimicrobial agents and chemotherapy.

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.

S. Hammer, M. Hirsch, D. Richman, 2000, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Adefovir for the treatment of HIV infection: if not now, when?

J. Mellors, 1999, JAMA.

Relationship between 3′-Azido-3′-Deoxythymidine Resistance and Primer Unblocking Activity in Foscarnet-Resistant Mutants of Human Immunodeficiency Virus Type 1 Reverse Transcriptase

J. Mellors, W. Scott, Holly Z. Bazmi, 2003, Journal of Virology.

Broad Advances in Understanding HIV Resistance to Antiretrovirals: Report on the XVII International HIV Drug Resistance Workshop

D. Richman, B. Larder, J. Mellors, 2008, Antiviral therapy.

In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase.

J. Mellors, Y. Cheng, E. Tramontano, 1992, Molecular pharmacology.

Population Pharmacokinetics and Pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir: Adult AIDS Clinical Trial Group Study 398

S. Hammer, J. Mellors, L. Sheiner, 2003, Antimicrobial Agents and Chemotherapy.

Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates

E. Arnold, J. Mellors, R. Schinazi, 1995, Antimicrobial agents and chemotherapy.

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.

Victor DeGruttola, Florin Vaida, S. Hammer, 2002, JAMA.

Better salvage therapy for HIV-1 infection still needed

J. Montaner, J. Mellors, 1999, The Lancet.

Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis

John W. Mellors, John M. Coffin, Sarah Palmer, 2005, Journal of Clinical Microbiology.

HIV Populations Are Large and Accumulate High Genetic Diversity in a Nonlinear Fashion

R. Stephens, J. Metcalf, R. Davey, 2013, Journal of Virology.

1 HIV Populations are Large and Accumulate High Genetic Diversity in Nonlinear

R. Stephens, J. Metcalf, R. Davey, 2013 .

Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance.

J. Mellors, N. Sluis-Cremer, J. Brehm, 2008, Biochemistry.

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

Victoria A Johnson, Daniel R Kuritzkes, Françoise Brun-Vézinet, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Synthesis and in vitro activity of long-chain 5'-O-[(alkoxycarbonyl)phosphinyl]-3'-azido-3'-deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1.

D. Richman, J. Mellors, K. Hostetler, 1997, Journal of medicinal chemistry.

A Randomized Trial of Nelfinavir and Abacavir in Combination with Efavirenz and Adefovir Dipivoxil in HIV-1-Infected Persons with Virological Failure Receiving Indinavir

S. Hammer, J. Mellors, K. Squires, 2002, Antiviral therapy.

Resistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidines

J. Mellors, R. Schinazi, M. Nguyen, 1994, Antimicrobial Agents and Chemotherapy.

Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet

J. Mellors, J. Mills, C. Birch, 1996, Journal of virology.

Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bond.

E. De Clercq, J. Mellors, J. Balzarini, 2004, Journal of medicinal chemistry.

A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).

J. Mellors, Y. Cheng, E. Tramontano, 1993, Molecular pharmacology.

Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000–2016: A Pooled Sequence Analysis

D. Katzenstein, R. Shafer, D. Pillay, 2019, EClinicalMedicine.

Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.

S. Hammer, F. Vaida, J. Mellors, 2010, The Journal of infectious diseases.

Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.

M. Hughes, R. Schooley, J. Mellors, 2014, The Journal of infectious diseases.

Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study

J. Margolick, J. Phair, S. O’Brien, 2001, AIDS.

Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1.

J. Mellors, J. Mills, C. Birch, 1995, Virology.

Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.

M. Hughes, J. Mellors, J. Hitti, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers

J. Mellors, G. Shaw, R. Ribeiro, 2016, PLoS pathogens.

Stavudine Resistance: An Update on Susceptibility following Prolonged Therapy

V. Calvez, M. Wainberg, V. Soriano, 1999, Antiviral therapy.

How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?

J. Mellors, U. Parikh, 2022, Current opinion in HIV and AIDS.

Effects of Specific Zidovudine Resistance Mutations and Substrate Structure on Nucleotide-Dependent Primer Unblocking by Human Immunodeficiency Virus Type 1 Reverse Transcriptase

J. Mellors, A. So, W. Scott, 2002, Antimicrobial Agents and Chemotherapy.

Zidovudine (AZT) Monotherapy Selects for the A360V Mutation in the Connection Domain of HIV-1 Reverse Transcriptase

S. Hammer, J. Mellors, N. Sluis-Cremer, 2012, PloS one.

Selection of Mutations in the Connection and RNase H Domains of Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Increase Resistance to 3′-Azido-3′-Dideoxythymidine

V. Pathak, J. Mellors, N. Sluis-Cremer, 2007, Journal of Virology.

Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision.

V. Pathak, J. Mellors, J. Coffin, 2005, Proceedings of the National Academy of Sciences of the United States of America.

A Novel Polymorphism at Codon 333 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Can Facilitate Dual Resistance to Zidovudine and l-2′,3′-Dideoxy-3′-Thiacytidine

John W. Mellors, Brendan A. Larder, Stuart Bloor, 1998, Journal of Virology.

Class-sparing regimens for initial treatment of HIV-1 infection.

Lynne Peeples, Richard Haubrich, Susan Swindells, 2008, The New England journal of medicine.

Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-Naïve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine

M. Lederman, D. Kuritzkes, J. Mellors, 2013, PloS one.

3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine

J. Mellors, J. Condra, J. Chodakewitz, 2000, Annals of Internal Medicine.

Natural history of HIV-1 infection.

J. Mellors, E. Vergis, Emanuel N. Vergis, 2000, Infectious disease clinics of North America.

Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.

Ashley J. Mayo, J. Baeten, A. van der Straten, 2016, The New England journal of medicine.

International AIDS Society global scientific strategy: towards an HIV cure 2016

Richard Jefferys, David Margolis, Jintanat Ananworanich, 2016, Nature Medicine.

Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.

S. Delany-Moretlwe, C. Petropoulos, J. Mellors, 2022, The Journal of infectious diseases.

Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?

J. Mellors, U. Parikh, Catherine A Koss, 2022, Current HIV/AIDS Reports.

E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings.

Michael I. Jordan, J. Mellors, N. Parkin, 2014, Antiviral research.

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.

J. Mellors, S. Swindells, A. DiRienzo, 2006, JAMA.

Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase

J. Mellors, Z. Ambrose, C. Kline, 2015, Antimicrobial Agents and Chemotherapy.

Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa

J. Mellors, C. Brumme, C. Wallis, 2018, Antiviral chemistry & chemotherapy.

Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.

R. Glaubius, U. Abbas, J. Mellors, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA).

J. Mellors, M. Boffito, D. Back, 2016, The Journal of infectious diseases.

Mutations in RT and Protease III -93 NOV 95 Mutations in HIV-1 Reverse Transcriptase and Protease Associated with Drug Resistance

B. Larder, J. Mellors, R. Schinazi, 1996 .

Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion

J. Mellors, Phalguni Gupta, C. Rinaldo, 1995, Annals of Internal Medicine.

Blinded, Multicenter Comparison of Methods To Detect a Drug-Resistant Mutant of Human Immunodeficiency Virus Type 1 at Low Frequency

Ingrid A. Beck, K. Metzner, V. Johnson, 2006, Journal of Clinical Microbiology.

In Vitro Selection of Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Decrease Susceptibility to (−)-β-d-Dioxolane-Guanosine and Suppress Resistance to 3′-Azido-3′-Deoxythymidine

J. Mellors, R. Schinazi, C. K. Chu, 2000, Antimicrobial Agents and Chemotherapy.

HIV-1 Infection Leads to Increased Transcription of Human Endogenous Retrovirus HERV-K (HML-2) Proviruses In Vivo but Not to Increased Virion Production

J. Mellors, J. Coffin, F. Maldarelli, 2014, Journal of Virology.

Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART

J. Mellors, J. Cyktor, Elizabeth Fyne, 2019, PloS one.

Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of Low-frequency drug resistance mutations in HIV-1 DNA

Claudia Stewart, Natalia Volfovsky, Wei Shao, 2013, Retrovirology.

Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study.

R H Lyles, A Muñoz, J. Margolick, 2000, The Journal of infectious diseases.

Trajectories of host-response biomarkers and inflammatory subphenotypes in COVID-19 patients across the spectrum of respiratory support

Janet S. Lee, J. Mellors, C. Kessinger, 2022, medRxiv.

Noninvasive diagnosis of secondary infections in COVID-19 by sequencing of plasma microbial cell-free DNA.

R. Duttagupta, J. Mellors, G. Kitsios, 2022, medRxiv.

Integration in oncogenes plays only a minor role in determining the in vivo distribution of HIV integration sites before or during suppressive antiretroviral therapy

S. Hughes, J. Mellors, B. Luke, 2021, PLoS pathogens.

Integration in or Near Oncogenes Plays Only a Minor Role in Determining the in Vivo Distribution of HIV Integration Sites Before or During Suppressive Antiretroviral Therapy

S. Hughes, J. Mellors, B. Luke, 2020, bioRxiv.

HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study

R. Siliciano, D. Richman, D. Kuritzkes, 2017, PLoS medicine.

The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption

M. Lederman, D. Kuritzkes, J. Mellors, 2015, AIDS.

The Viral Activation Transfusion Study (VATS): rationale, objectives, and design overview

J. Mellors, T. Flanigan, R. Pollard, 1996, Transfusion.

Human retroviruses and AIDS 1996. A compilation and analysis of nucleic acid and amino acid sequences

John W. Mellors, Brian T. Foley, Bette T. Korber, 1997 .

Mechanistic Analysis of the Broad Antiretroviral Resistance Conferred by HIV-1 Envelope Glycoprotein Mutations

J. Mellors, E. Freed, Y. Hikichi, 2020, mBio.

Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration

Daniel R Kuritzkes, Ruy M Ribeiro, Alan S Perelson, 2017, PLoS pathogens.

Retrovirus Integration Database (RID): a public database for retroviral insertion sites into host genomes

John W. Mellors, John M. Coffin, Wei Shao, 2016, Retrovirology.

Reversal of T-cell exhaustion as a strategy to improve immune control of HIV-1.

J. Mellors, John K. Bui, 2015, AIDS.

Vif and the Role of Antiviral Cytidine Deaminases in HIV-1 Replication

J. Mellors, A. Meyerhans, S. Wain-Hobson, 2004 .

Clones of infected cells arise early in HIV-infected individuals.

S. Hughes, J. Mellors, B. Luke, 2019, JCI insight.

Proviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoir

S. Hughes, J. Mellors, B. Luke, 2017, PLoS pathogens.

Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo

S. Hughes, J. Kovacs, M. Polis, 2016, Proceedings of the National Academy of Sciences.

Specific HIV integration sites are linked to clonal expansion and persistence of infected cells

S. Hughes, J. Mellors, J. Coffin, 2014, Science.

Towards an HIV cure: a global scientific strategy

M. Lederman, J. Mullins, A. Telenti, 2012, Nature Reviews Immunology.

HIV Infected T Cells Can Proliferate in vivo Without Inducing Expression of the Integrated Provirus

S. Hughes, E. Boritz, J. Mellors, 2019, Front. Microbiol..

Prognostic value of plasma HIV RNA in the natural history of Pneumocystis carinii pneumonia, cytomegalovirus and Mycobacterium avium complex

J. Margolick, J. Phair, R. Detels, 1999 .

Predictive Value of Immunologic and Virologic Markers After Long or Short Duration of HIV‐1 Infection

John W. Mellors, Robert H. Lyles, Traci E. Yamashita, 2002, Journal of acquired immune deficiency syndromes.

The emerging plasticity of SARS-CoV-2

J. Mellors, K. McCormick, J. Jacobs, 2021, Science.

Insertional activation of STAT3 and LCK by HIV-1 proviruses in T cell lymphomas

Beth A. Scott, S. Hughes, J. Mellors, 2021, Science advances.

Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control.

C. Hallahan, S. Migueles, M. Connors, 2008, Immunity.

Majority of CD4+ T cells from peripheral blood of HIV-1–infected individuals contain only one HIV DNA molecule

Wei Shao, Jan Albert, Jianbo Chen, 2011, Proceedings of the National Academy of Sciences.

Ultrasensitive Allele-Specific PCR Reveals Rare Preexisting Drug-Resistant Variants and a Large Replicating Virus Population in Macaques Infected with a Simian Immunodeficiency Virus Containing Human Immunodeficiency Virus Reverse Transcriptase

J. Mellors, J. Coffin, V. KewalRamani, 2012, Journal of Virology.

OPINION Adaptation of advanced clinical virology assays from HIV-1 to SARS-CoV-2

J. Mellors, K. McCormick, J. Jacobs, 2021 .

Adaptation of advanced clinical virology assays from HIV-1 to SARS-CoV-2

J. Mellors, K. McCormick, J. Jacobs, 2020, Current opinion in HIV and AIDS.

A Simpler and More Sensitive Single-Copy HIV-1 RNA Assay for Quantification of Persistent HIV-1 Viremia in Individuals on Suppressive Antiretroviral Therapy

J. Mellors, K. Shutt, J. Cyktor, 2019, Journal of Clinical Microbiology.

The need for treatment interruption studies and biomarker identification in the search for an HIV cure.

J. Mellors, Davey M. Smith, Jonathan Z. Li, 2015, AIDS.

1 Title : Improved Single Copy Assays for Quantification of Persistent HIV-1 Viremia in 1 Patients on Suppressive Antiretroviral Therapy 2 3

J. Mellors, J. Coffin, M. Piatak, 2014 .

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

S J Gange, M A Proschan, R. Siliciano, 2009, Proceedings of the National Academy of Sciences.

Estimation of the Predictive Role of Plasma Viral Load on CD4 Decline in HIV-1 Subtype C-Infected Subjects in India

J. Mellors, Phalguni Gupta, Yue Chen, 2009, Journal of Acquired Immune Deficiency Syndromes.

Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection.

Roger Detels, Lisa P Jacobson, J. Margolick, 2007, JAMA.

Distribution of Chemokine Receptor CCR2 and CCR5 Genotypes and Their Relative Contribution to Human Immunodeficiency Virus Type 1 (HIV-1) Seroconversion, Early HIV-1 RNA Concentration in Plasma, and Later Disease Progression

J. Goedert, Y. Zhang, J. Margolick, 2002, Journal of Virology.

Virologic, immunologic, and immune activation markers as predictors of HIV-associated weight loss prior to AIDS. Multicenter AIDS Cohort Study.

J. Margolick, J. Phair, J. Mellors, 1999, Journal of acquired immune deficiency syndromes.

Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.

L. Markson, J. Mellors, E. Dasbach, 1999, AIDS research and human retroviruses.

Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV‐1 infection

M. Carrington, J. Phair, R. Detels, 1998, AIDS.

Distribution of Brain HIV Load in AIDS

E. Masliah, J. Mellors, C. Achim, 1998, Brain pathology.

Well-mixed plasma and tissue viral populations in RT-SHIV-infected macaques implies a lack of viral replication in the tissues during antiretroviral therapy

J. Mellors, J. Coffin, Z. Ambrose, 2015, Retrovirology.

Lack of Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral Therapy

J. Mellors, J. Coffin, Nicholas A. Kovacs, 2014, PLoS pathogens.

Genetic Diversity of Simian Immunodeficiency Virus Encoding HIV-1 Reverse Transcriptase Persists in Macaques despite Antiretroviral Therapy

J. Lifson, J. Mellors, J. Coffin, 2010, Journal of Virology.

Prioritizing Pregnant Women for Coronavirus Disease 2019 Vaccination in African Countries

J. Nachega, J. Mellors, L. Mofenson, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Novel Criteria for Diagnosing Acute and Early HIV Infection in a Multi-National Study of Early Antiretroviral Therapy Initiation.

B. Chi, J. Ananworanich, K. Ruxrungtham, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Dendritic cells focus CTL responses toward highly conserved and topologically important HIV epitopes

B. Walker, B. Korber, J. Ananworanich, 2020, bioRxiv.

Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption

M. Carrington, D. Kuritzkes, J. Mellors, 2017, Pathogens & immunity.

RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy

Wei Shao, R. Stephens, J. Lifson, 2009, Retrovirology.

Key Reports from the XV International HIV Drug Resistance Workshop 2006

D. Richman, B. Larder, J. Mellors, 2007, Antiviral therapy.

A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo.

D. Dimitrov, J. Mellors, R. Ishima, 2021, Cancer letters.

Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies.

J. Mellors, R. Bosch, Davey M. Smith, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Intact HIV Proviruses Persist in Children Seven to Nine Years after Initiation of Antiretroviral Therapy in the First Year of Life

Wei-Shau Hu, J. Mellors, Imogen A. Wright, 2019, Journal of Virology.

Associations between HIV-1 DNA copy number, proviral transcriptional activity, and plasma viremia in individuals off or on suppressive antiretroviral therapy.

J. Mellors, Lu Zheng, A. Cillo, 2018, Virology.

Blood biomarkers of expressed and inducible HIV-1

J. Mellors, R. Geleziunas, T. Cihlar, 2018, AIDS.

Viral-load tests provide valuable answers.

J. Mellors, J W Mellors, 1998, Scientific American.

Quantitation of human immunodeficiency virus type 1 DNA and RNA by a novel internally controlled PCR assay

L. Kingsley, Steven Wolinsky, J. Mellors, 1995, Journal of clinical microbiology.

Natural History of Human Immunodeﬁciency Virus Type 1 Viremia after Seroconversion and Proximal to AIDS in a Large Cohort of Homosexual Men

J. Margolick, J. Phair, R. Detels, 2022 .

Simian Immunodeficiency Virus SIVsab Infection of Rhesus Macaques as a Model of Complete Immunological Suppression with Persistent Reservoirs of Replication-Competent Virus: Implications for Cure Research

J. Mellors, C. Apetrei, I. Pandrea, 2015, Journal of Virology.

Use of External Quality Control Material for HIV-1 RNA Testing To Assess the Comparability of Data Generated in Separate Laboratories and the Stability of HIV-1 RNA in Samples after Prolonged Storage

J. Mellors, J. Bremer, C. Wager, 2018, Journal of Clinical Microbiology.

A cure for HIV: what will it take?

J. Ananworanich, J. Mellors, 2015, Current opinion in HIV and AIDS.

Performance of Swabs, Lavage, and Diluents to Quantify Biomarkers of Female Genital Tract Soluble Mucosal Mediators

J. Mellors, J. Marrazzo, C. Hendrix, 2011, PloS one.

Discovery of a Small Molecule Agonist of Phosphatidylinositol 3-Kinase p110α That Reactivates Latent HIV-1

J. Mellors, K. Huber, N. Sluis-Cremer, 2014, PloS one.

Viremic relapse after HIV-1 remission in a perinatally infected child.

Katherine Luzuriaga, Kaitlin Rainwater-Lovett, J. Mellors, 2015, The New England journal of medicine.

Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248.

M. Lederman, D. Kuritzkes, C. Flexner, 2013, The Journal of infectious diseases.

Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy

M. Lederman, J. Mellors, J. Coffin, 2015, Journal of Virology.

Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines

N. Ford, J. D. da Silva, A. Wensing, 2020, The lancet. HIV.

Ultrasensitive single-genome sequencing: accurate, targeted, next generation sequencing of HIV-1 RNA

J. Mellors, J. Coffin, F. Maldarelli, 2016, Retrovirology.

Varied Patterns of HIV-1 Drug Resistance on Failing First-Line Antiretroviral Therapy in South Africa

Ian Sanne, Wendy Stevens, J. Mellors, 2010, Journal of acquired immune deficiency syndromes.

Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial.

M. Reitsma, J. Mellors, R. Kantor, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Rapid decline of HIV-1 DNA and RNA in infants starting very early antiretroviral therapy may pose a diagnostic challenge

J. Mellors, M. Cotton, B. Laughton, 2018, AIDS.

HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy.

S. Hughes, J. Mellors, J. Coffin, 2019, The Journal of clinical investigation.

HIV-1 in Lymph Nodes is Maintained by Cellular Proliferation During Antiretroviral 1 Therapy 2 3

Patro, S. Hughes, J. Mellors, 2019 .

CD4+CD73+ T cells are associated with lower T-cell activation and C reactive protein levels and are depleted in HIV-1 infection regardless of viral suppression

J. Mellors, C. Rinaldo, T. Whiteside, 2013, AIDS.

Predicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithm

J. Mellors, M. Weinberger, W. Miller, 2016, BMC Infectious Diseases.

Which therapeutic strategy will achieve a cure for HIV-1?

J. Mellors, A. Cillo, 2016, Current opinion in virology.

Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy

Anthony R Cillo, Ronald J Bosch, J. Mellors, 2014, Proceedings of the National Academy of Sciences.

Linked dual-class HIV resistance mutations are associated with treatment failure.

M. Hughes, R. Schooley, J. Mellors, 2019, JCI insight.

HIV-1 Virion Production from Single Inducible Proviruses following T-Cell Activation Ex Vivo

J. Mellors, A. Cillo, John K. Bui, 2015, Journal of Virology.

Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase

R. Haubrich, M. Lederman, J. Mellors, 2000, AIDS.

A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy.

M. Hirsch, B. Hirschel, S. Staszewski, 1999, The Journal of infectious diseases.

Suppression of Viremia and Evolution of Human Immunodeficiency Virus Type 1 Drug Resistance in a Macaque Model for Antiretroviral Therapy

J. Lifson, J. Mellors, J. Coffin, 2007, Journal of Virology.

Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the MTN-020/ASPIRE Phase III Trial of the Dapivirine Vaginal Ring.

Ashley J. Mayo, J. Baeten, J. Mellors, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV RNA screening reduces integrase strand transfer inhibitor resistance risk in persons receiving long-acting cabotegravir for HIV prevention.

J. Mellors, M. Marzinke, R. Landovitz, 2022, The Journal of infectious diseases.

Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users

J. Margolick, J. Phair, R. Detels, 2004, AIDS.

HIV-1 viral load and clinical outcome: review of recent studies.

J. Mellors, S. Riddler, 1997, AIDS.

Casting a Wide Net: HIV Drug Resistance Monitoring in Pre-Exposure Prophylaxis Seroconverters in the Global Evaluation of Microbicide Sensitivity Project

J. Mellors, B. Chohan, Everline C Bosek, 2022, Global Health: Science and Practice.

ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia

Joseph A Kovacs, Sarah Palmer, R. Dewar, 2007, PLoS pathogens.

Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial

R. Schooley, R. Gross, J. Mellors, 2022, Journal of the International AIDS Society.

Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance

R. Gross, J. Mellors, A. Collier, 2023, AIDS Research and Therapy.

Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.

J. Mellors, A. Collier, B. Taiwo, 2016, The lancet. HIV.

Lower pre-ART intra-participant HIV-1 pol diversity may not be associated with virologic failure in adults

M. Hughes, R. Haubrich, J. Mellors, 2018, PloS one.

Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa

J. Mellors, W. Venter, I. Sanne, 2010, AIDS research and treatment.

Natural Killer Cell Receptors and Ligands Are Associated With Markers of HIV-1 Persistence in Chronically Infected ART Suppressed Patients

J. Mellors, S. Holmes, R. Bosch, 2022, Frontiers in Cellular and Infection Microbiology.

Plasma Viremia and Cellular HIV-1 DNA Persist Despite Autologous Hematopoietic Stem Cell Transplantation for HIV-Related Lymphoma

A. Krishnan, J. Mellors, J. Rossi, 2013, Journal of acquired immune deficiency syndromes.

Discovery and pre-clinical evaluation of antibodies to the NKG2A inhibitory receptor

D. Dimitrov, J. Mellors, J. Cyktor, 2022, bioRxiv.

No evidence that circulating HIV-specific immune responses contribute to persistent inflammation and immune activation in persons on long-term ART

J. Mellors, R. Bosch, R. B. Jones, 2021, AIDS.

Regulatory T cells: the ultimate HIV reservoir?

J. Mellors, J. Rocco, B. Macatangay, 2018, Journal of virus eradication.

Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts.

A Muñoz, J. Margolick, J. Phair, 2001, American journal of epidemiology.

Janet S. Lee, J. Mellors, P. Bjorkman, 2021, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation

J. Mellors, R. Bosch, C. Rinaldo, 2017, PLoS pathogens.

Baseline Natural Killer and T Cell Populations Correlation with Virologic Outcome after Regimen Simplification to Atazanavir/Ritonavir Alone (ACTG 5201)

J. Mellors, C. Rinaldo, S. Swindells, 2014, PloS one.

Potential Impact of Antiretroviral Therapy on HIV-1 Transmission and AIDS Mortality in Resource-Limited Settings

R. Anderson, U. Abbas, J. Mellors, 2006, Journal of acquired immune deficiency syndromes.

Short-Course Combivir after Single-Dose Nevirapine Reduces but Does Not Eliminate the Emergence of Nevirapine Resistance in Women

J. Mellors, J. Coffin, G. Gray, 2012, Antiviral therapy.

Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir

S. Hammer, J. Mellors, L. Sheiner, 2002, Clinical pharmacology and therapeutics.

Anti-Human Immunodeficiency Virus Type 1 (HIV-1) CD8+ T-Lymphocyte Reactivity during Combination Antiretroviral Therapy in HIV-1-Infected Patients with Advanced Immunodeficiency

J. Margolick, J. Mellors, C. Rinaldo, 2000, Journal of Virology.

HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy

J. Mellors, R. Bosch, A. Danesh, 2021, JCI insight.

Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy.

J. Siliciano, J. Mellors, R. Bosch, 2020, The Journal of infectious diseases.

HIV-1 Viremia Not Suppressible By Antiretroviral Therapy Can Originate from Large T-Cell Clones Producing Infectious Virus

S. Hughes, J. Mellors, J. Coffin, 2020, bioRxiv.

Naïve CD4+ T Cells Harbor a Large Inducible Reservoir of Latent, Replication-Competent HIV-1.

J. Mellors, N. Sluis-Cremer, D. McMahon, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

No evidence of HIV replication in children on antiretroviral therapy.

J. Mellors, B. Luke, J. Coffin, 2017, The Journal of clinical investigation.

HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy.

J. Mellors, R. Bosch, S. Riddler, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

Cheryl Jennings, Ian B Hogue, Sarah Palmer, 2005, The Lancet.

Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA

R. Siliciano, L. Montaner, J. Blankson, 2020, Proceedings of the National Academy of Sciences.

HIV Proviral Sequence Database (PSD): A New Public Database for Near Full-Length HIV Proviral Sequences and Their Meta-Analyses.

Wei-Shau Hu, J. Mellors, J. Coffin, 2020, AIDS research and human retroviruses.

HIV-1 remission and possible cure in a woman after haplo-cord blood transplant

J. Mellors, D. Persaud, N. Tobin, 2023, Cell.

Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing

C. Spina, J. Mellors, Helen Yu, 2014, PLoS pathogens.

Inhibitors of Histone Deacetylases

J. Mellors, K. Huber, N. Sluis-Cremer, 2011, The Journal of Biological Chemistry.

Deep Sequencing Analysis of Individual HIV-1 Proviruses Reveals Frequent Asymmetric Long Terminal Repeats

S. Mallal, J. Mellors, J. Coffin, 2022, Journal of virology.

Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

S J Gange, S. Gange, J. Metcalf, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Intact HIV Proviruses Persist in Children 7-9 Years after Initiation of ART in the First Year of Life

Wei-Shau Hu, J. Mellors, Imogen A. Wright, 2019, SSRN Electronic Journal.

Ongoing HIV Replication During ART Reconsidered

J. Mellors, B. Luke, J. Coffin, 2017, Open forum infectious diseases.

No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1–Infected Patients Receiving Antiretroviral Therapy

John W. Mellors, Robert W. Coombs, Michael M. Lederman, 2012, Journal of acquired immune deficiency syndromes.

Changes in HIV reservoirs during long-term antiretroviral therapy

J. Mellors, Feiyu F Hong, 2015, Current opinion in HIV and AIDS.

OP 1.3 – 00017 The fraction of cells with unspliced HIV RNA is not associated with plasma viremia

J. Mellors, J. Coffin, W. Shao, 2022, Journal of virus eradication.

T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy

B. Walker, C. Kovacs, J. Mellors, 2017, PLoS pathogens.

HIV infected CD4+ T cell clones are more stable than uninfected clones during long-term antiretroviral therapy

S. Hughes, D. Douek, J. Mellors, 2022, PLoS pathogens.

Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors

J. Mellors, R. Bosch, Shauna Clark, 2006, AIDS.

Genetic correlates of efavirenz hypersusceptibility

Ronald J Bosch, D. Katzenstein, J. Mellors, 2004, AIDS.

Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size

Michael P. Busch, Jun Lai, John W. Mellors, 2018, bioRxiv.

Construction of a Large Size Human Immunoglobulin Heavy Chain Variable (VH) Domain Library, Isolation and Characterization of Novel Human Antibody VH Domains Targeting PD-L1 and CD22

D. Dimitrov, J. Mellors, R. Orentas, 2022, Frontiers in Immunology.

Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates

D. Dimitrov, J. Mellors, D. Zhelev, 2023, Frontiers in Oncology.

CD8+ T-Cell Gamma Interferon Production Specific for Human Immunodeficiency Virus Type 1 (HIV-1) in HIV-1-Infected Subjects

J. Mellors, C. Rinaldo, Xiao-li Huang, 2000, Clinical Diagnostic Laboratory Immunology.

627. Tele-OPAT Outcomes at Two Community Hospitals

J. Mellors, Nupur Gupta, K. Sheridan, 2020 .

Impact of Chemotherapy for HIV-1 Related Lymphoma on Residual Viremia and Cellular HIV-1 DNA in Patients on Suppressive Antiretroviral Therapy

J. Mellors, M. Para, A. Cillo, 2014, PloS one.

Comparison of methods to quantify inducible HIV-1 outgrowth

J. Mellors, J. Eron, R. Gandhi, 2021, Journal of virus eradication.

Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains

M. H. Cheng, S. Subramaniam, I. Bahar, 2022, bioRxiv.

SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization

S. Subramaniam, D. Dimitrov, J. Mellors, 2022, Nature Communications.

Potential Impact of Antiretroviral Chemoprophylaxis on HIV-1 Transmission in Resource-Limited Settings

Roy M. Anderson, John W. Mellors, Ume L. Abbas, 2007, PloS one.

How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts’ Opinion and Its Influence on the Projected Public Health Impact

T. Hallett, D. Pillay, J. Mellors, 2016, PloS one.

Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa.

Robert Glaubius, Anuj Mubayi, Gregory Hood, 2013, The Journal of infectious diseases.

Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities

M. Dybul, J. Mellors, P. Piot, 2010, Journal of the International AIDS Society.

Tracking HIV-1-Infected Cell Clones Using Integration Site-Specific qPCR

S. Hughes, J. Mellors, J. Coffin, 2021, Viruses.

Persistence of Viral Reservoirs in Multiple Tissues after Antiretroviral Therapy Suppression in a Macaque RT-SHIV Model

J. Lifson, J. Mellors, M. Piatak, 2013, PloS one.

Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?

J. Mellors, S. Vasan, D. Hsu, 2021, Frontiers in Immunology.

Cellular HIV RNA/DNA as biomarkers of inducible virion production

J. Mellors, J. Lalezari, A. Cillo, 2015 .

Temporal Changes in Clinical Practice with COVID-19 Hospitalized Patients: Potential Explanations for Better In-Hospital Outcomes

D. Yealy, G. Snyder, J. Mellors, 2020, medRxiv.

Longitudinal patterns of HIV type 1 RNA among individuals with late disease progression.

J. Margolick, B. Lau, J. Phair, 2001, AIDS research and human retroviruses.

The ART of preventing HIV

J. Mellors, S. Deeks, 2011, Nature Medicine.

HIV-1 remission and possible cure in a woman after haplo-cord blood transplant

J. Mellors, D. Persaud, N. Tobin, 2023, Cell.

Objective Measurement of Inaccurate Condom Use Reporting Among Women Using Depot Medroxyprogesterone Acetate for Contraception

J. Baeten, R. Heffron, J. Mellors, 2017, AIDS and Behavior.

Prevalence of HIV-1 Drug Resistance among Women Screening for HIV Prevention Trials in KwaZulu-Natal, South Africa (MTN-009)

J. Mellors, P. Kiepiela, C. Kelly, 2013, PloS one.

Y Chromosome and HIV DNA Detection in Vaginal Swabs as Biomarkers of Semen and HIV Exposure in Women

J. Mellors, B. Richardson, S. A. Abdool Karim, 2014, Sexually transmitted diseases.

Effect of stavudine on human immunodeficiency virus type 1 virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune complex-dissociated antigenemia.

J. Mellors, Y. Cheng, P. Alcabes, 1996, The Journal of infectious diseases.

A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors

J. Mellors, C. Shi, 1997, Antimicrobial agents and chemotherapy.

Clinical Efficacy of Monotherapy with Stavudine Compared with Zidovudine in HIV-Infected, Zidovudine-Experienced Patients

A. Cross, J. Mellors, E. Stool, 1997, Annals of Internal Medicine.

Accuracy of the TRUGENE HIV-1 Genotyping Kit

V. Johnson, D. Kuritzkes, R. Grant, 2003, Journal of Clinical Microbiology.

In vitro Anti-HIV-1 Activity of sn-2-Substituted 1-O-Octadecyl-sn-Glycero-3-Phosphonoformate Analogues and Synergy with Zidovudine

D. Richman, T. Chou, J. Mellors, 2000, Antiviral chemistry & chemotherapy.

In Vitro Activity of Structurally Diverse Nucleoside Analogs against Human Immunodeficiency Virus Type 1 with the K65R Mutation in Reverse Transcriptase

J. Mellors, R. Schinazi, C. K. Chu, 2005, Antimicrobial Agents and Chemotherapy.

Single Genome Sequencing of HIV-1 Gag and Protease Resistance Mutations at Virologic Failure during the Ok04 Trial of Simplified versus Standard Maintenance Therapy

J. Mellors, J. Arribas, R. Delgado, 2011, Antiviral therapy.

Antibody Responses After mRNA-Based COVID-19 Vaccination in Residential Older Adults: Implications for Reopening

Octavia M Peck Palmer, J. Mellors, K. Kip, 2021, Journal of the American Medical Directors Association.

HIV-specific T-cell responses reflect substantive in vivo interactions with infected cells despite long-term therapy

J. Mellors, R. Bosch, A. Danesh, 2020 .

HIV-Infected African Americans are Willing to Participate in HIV Treatment Trials

B. Hanusa, J. Mellors, R. Arnold, 2007, Journal of General Internal Medicine.

Prospective evaluation of COVID-19 vaccine responses across a broad spectrum of immunocompromising conditions: the COVICS study.

D. Angus, J. Luketich, M. Schwartz, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy.

S. Hammer, D. Richman, D. Havlir, 2001, The Journal of infectious diseases.

Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine

D. Richman, D. Havlir, J. Mellors, 2003, AIDS.

Antiretroviral Activity and Safety of Abacavir in Combination with Selected HIV-1 Protease Inhibitors in Therapy-Naive HIV-1-Infected Adults

R. Haubrich, M. Lederman, J. Mellors, 2000, Antiviral therapy.

Prognostic value of plasma HIV RNA in the natural history of Pneumocystis carinii pneumonia, cytomegalovirus and Mycobacterium avium complex. Multicenter AIDS Cohort Study.

J. Margolick, J. Phair, R. Detels, 1999, AIDS.

reportPlanning for pre-exposure prophylaxis to prevent HIV transmission : challenges and opportunities

M. Dybul, J. Mellors, P. Piot, 2010 .

Positron emission tomography imaging of peripheral benzodiazepine receptor binding in human immunodeficiency virus-infected subjects with and without cognitive impairment

S. Wisniewski, J. Becker, O. Lopez, 2006, Journal of NeuroVirology.

Human Antibody VH Domains Targeting GPNMB and VCAM-1 as Candidate Therapeutics for Cancers

D. Dimitrov, J. Mellors, I. Lyakhov, 2023, Molecular pharmaceutics.

Randomized Study of Dual Versus Single Ritonavir-Enhanced Protease Inhibitors for Protease Inhibitor-Experienced Patients with HIV

J. Mellors, A. Collier, K. Klingman, 2008, HIV clinical trials.

Antiretroviral therapy for previously treated patients.

J. Montaner, J. Mellors, 2001, The New England journal of medicine.

In-Person Versus Tele-Infectious Disease (Tele-ID) Care: Is One Better?

J. Mellors, J. Bariola, Nupur Gupta, 2022, Open forum infectious diseases.

Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Pregnancy in Sub-Saharan Africa: A 6-Country Retrospective Cohort Analysis

J. Stringer, L. Myer, A. Kengne, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo

J. Nachega, J. Mellors, L. Mofenson, 2020, The American journal of tropical medicine and hygiene.

Visions for the future of antiretroviral therapy

U. Abbas, J. Mellors, 2004 .

Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens.

J. Mellors, C. Rinaldo, S. Riddler, 1999, The Journal of infectious diseases.

Recovery of replication-competent HIV type 1-infected circulating monocytes from individuals receiving antiretroviral therapy.

J. Becker, J. Mellors, C. Achim, 2002, AIDS research and human retroviruses.

Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study

T. Hallett, D. Havlir, J. Mellors, 2022, The lancet. HIV.

Restoration of Anti-Human Immunodeficiency Virus Type 1 (HIV-1) Responses in CD8+ T Cells from Late-Stage Patients on Prolonged Antiretroviral Therapy by Stimulation In Vitro with HIV-1 Protein-Loaded Dendritic Cells

J. Mellors, C. Rinaldo, Xiao-li Huang, 2001, Journal of Virology.

A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.

Florin Vaida, Diane V Havlir, M. Lederman, 2006, The Journal of infectious diseases.

Allogeneic hematopoietic cell transplant (alloHCT) for hematologic malignancies in human immunodeficiency virus infected (HIV) patients (pts): Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0903)/AIDS Malignancy Consortium (AMC-080) trial.

J. Mellors, M. Horowitz, U. Popat, 2017 .

Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase

Wei Shao, Sarah Palmer, J. Margolick, 2008, AIDS.

Intact proviral DNA levels decline in people with HIV on antiretroviral therapy

R. Siliciano, J. Mellors, R. Bosch, 2019 .

Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design.

J. Mellors, J. Coffin, L. Morris, 2010, Journal of virological methods.

The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies

B. Walker, R. Schooley, S. Little, 2018, The Journal of infectious diseases.

Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b)

A. Perelson, D. Kuritzkes, J. Mellors, 2015, AIDS.

Article type: Short communication Title: Neutralization of European, South African, and United States SARS-CoV-2 mutants by a human antibody and antibody domains Authors:

D. Dimitrov, J. Mellors, K. McCormick, 2021 .

Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

J. Mellors, C. Hendrix, M. Marzinke, 2023, Antimicrobial agents and chemotherapy.

Automated Multireplicate Quantification of Persistent HIV-1 Viremia in Individuals on Antiretroviral Therapy

J. Mellors, K. Shutt, M. Busch, 2020, Journal of Clinical Microbiology.

No cure yet for HIV-1, but therapeutic research presses on.

R. Schooley, J. Mellors, 2007, The Journal of infectious diseases.

Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity

V. Johnson, J. Mellors, J. Bremer, 2015, Journal of Clinical Microbiology.

Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size

Daniel I. S. Rosenbloom, R. Ptak, D. Richman, 2020, The Journal of infectious diseases.

Current HIV/SIV Reservoir Assays for Preclinical and Clinical Applications: Recommendations from the Experts 2022 NIAID Workshop Summary.

Brigitte E. Sanders-Beer, R. Siliciano, J. Karn, 2023, AIDS research and human retroviruses.

Performance of Celera RUO integrase resistance assay across multiple HIV-1 subtypes.

J. Mellors, C. Wallis, C. Zeh, 2017, Journal of virological methods.

A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Hiv-Associated Chronic Inflammation.

Kaleab Z. Abebe, J. Mellors, C. Rinaldo, 2019, The Journal of infectious diseases.

Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy.

F. Vaida, J. Mellors, R. Bosch, 2016, The Journal of infectious diseases.

Residual Plasma Viraemia and Infectious HIV-1 Recovery from Resting Memory CD4 Cells in Patients on Antiretroviral Therapy: Results from ACTG A5173

R. Siliciano, J. Siliciano, J. Mellors, 2013, Antiviral therapy.

New Tools for Quantifying HIV-1 Reservoirs: Plasma RNA Single Copy Assays and Beyond

J. Mellors, A. Cillo, Benedict B Hilldorfer, 2012, Current HIV/AIDS Reports.

Predictors of Residual Viremia in Patients on Long-term Suppressive Antiretroviral Therapy

J. Mellors, R. Bosch, J. Eron, 2013 .

Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog

J. Mellors, N. Sluis-Cremer, Geneviève Doyon, 2013, AIDS.

Ex vivo activation of CD4+ T-cells from donors on suppressive ART can lead to sustained production of infectious HIV-1 from a subset of infected cells

J. Mellors, B. Luke, W. Shao, 2017, PLoS pathogens.

Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of Low-frequency drug resistance mutations in HIV-1 DNA

R. Stephens, J. Mellors, N. Volfovsky, 2013, Retrovirology.

No Evidence for an Association between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART

J. Mellors, R. Bosch, C. Rinaldo, 2019, Journal of acquired immune deficiency syndromes.

Lipid Treatment Goals Achieved in Patients Treated With Statin Drugs in Norwegian General Practice

Karen M. Daley, L. Goldman, M. Weisberg, 2000 .

HIV‐1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial

J. Baeten, D. Szydlo, J. Mellors, 2021, Journal of the International AIDS Society.

Sensitive Phenotypic Detection of Minor Drug-Resistant Human Immunodeficiency Virus Type 1 Reverse Transcriptase Variants

D. Garfinkel, J. Strathern, J. Mellors, 2005, Journal of Clinical Microbiology.

Effects of Anticoagulant, Processing Delay, and Assay Method (Branched DNA versus Reverse Transcriptase PCR) on Measurement of Human Immunodeficiency Virus Type 1 RNA Levels in Plasma

J. Margolick, J. Phair, R. Hogg, 1999, Journal of Clinical Microbiology.

Simplification Strategies to Reduce Antiretroviral drug Exposure: Progress and Prospects

J. Mellors, S. Swindells, J. McKinnon, 2009, Antiviral therapy.

Nevirapine- Versus Lopinavir/Ritonavir-Based Initial Therapy for HIV-1 Infection among Women in Africa: A Randomized Trial

M. Hughes, R. Schooley, J. Mellors, 2012, PLoS medicine.

High Levels of Pretreatment HIV-1 Drug Resistance Mutations Among South African Women Who Acquired HIV During a Prospective Study

J. Baeten, R. Heffron, H. Rees, 2022, Journal of acquired immune deficiency syndromes.

Nonhuman Primate Models for HIV Cure Research

J. Mellors, C. Apetrei, I. Pandrea, 2012, PLoS pathogens.

Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection

R. Haubrich, D. Havlir, J. Mellors, 2011, AIDS.

Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy

Sarah Palmer, R. Dewar, J. Metcalf, 2006, AIDS.

HIV and Hepatitis Virus Resistance to Antivirals: Review of Data from the Xix International HIV and Hepatitis Virus Drug Resistance Workshop and Curative Strategies

D. Richman, B. Larder, J. Mellors, 2011, Antiviral therapy.

Effective Salvage Therapy for HIV-1 Infection – An Unmet Challenge

J. Montaner, J. Mellors, 1998, Antiviral therapy.

HIV persistence in the CNS: the final frontier for a cure?

S. Lewin, J. Mellors, 2016, Journal of virus eradication.

Track C Epidemiology and Prevention Science

David R. Holtgrave, W. Heneine, Y. Nakamura, 2012, Journal of the International AIDS Society.

Retrovirus Integration Database (RID): a public database for retroviral insertion sites into host genomes

S. Hughes, J. Mellors, B. Luke, 2016, Retrovirology.

Brief Report: Dipyridamole Decreases Gut Mucosal Regulatory T-Cell Frequencies Among People With HIV on Antiretroviral Therapy.

Kaleab Z. Abebe, J. Mellors, S. Riddler, 2020, Journal of acquired immune deficiency syndromes.

Plasma SARS-CoV-2 RNA levels as a biomarker of lower respiratory tract SARS-CoV-2 infection in critically ill patients with COVID-19.

Janet S. Lee, J. Mellors, A. Naqvi, 2022, medRxiv.

The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy

T. Wrin, J. Mellors, R. Begley, 2021, Science Translational Medicine.

Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART

A. Perelson, R. Koup, J. Casazza, 2018, Open forum infectious diseases.

Clinical Implications of Resistance to Antiretrovirals: New Resistance Technologies and Interpretations

D. Richman, B. Larder, J. Mellors, 2008, Antiviral therapy.

Salvage therapy for HIV-1 infection—the challenge grows

J. Montaner, J. Mellors, 2000, The Lancet.

Acute human immunodeficiency virus infection: false-negative ELISA in a patient with viremia and a positive western blot test.

J. Mellors, B. Griffith, D. Ferguson, 1989, The Journal of infectious diseases.

Feasibility of a targeted, very early infant HIV diagnosis algorithm in a resource-limited setting

J. Nachega, J. Mellors, M. Cotton, 2014 .

Prognostic value of combined response markers among human immunodeficiency virus-infected persons: possible aid in the decision to change zidovudine monotherapy.

J. Phair, S. Piantadosi, J. Mellors, 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Closing in on human immunodeficiency virus–1

J. Mellors, 1996, Nature Medicine.

Comparative sensitivity of automated (Abbott M2000) and manual plasma HIV-1 RNA PCR assays for the detection of persistent viremia after long-term antiretroviral therapy

J. Mellors, R. Bosch, J. Eron, 2022, Journal of virus eradication.

Proceedings of the Frontiers of Retrovirology Conference 2016

Sebastian A. Wagner, R. König, D. Elleder, 2016, Retrovirology.

Virologic and immunologic values allowing safe deferral of antiretroviral therapy

J. Margolick, J. Phair, R. Detels, 2002, AIDS.

INHIBITORS OF HISTONE DEACETYLASES : CORRELATION BETWEEN ISOFORM SPECIFICITY AND REACTIVATION OF HIV-1 FROM LATENTLY INFECTED CELLS *

J. Mellors, K. Huber, N. Sluis-Cremer, 2011 .

antiviral agent that may be used in combination with antiretroviral therapy.

D. Havlir, J. Mellors, T. Akaike, 2015 .

Diverse HIV-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line ART in Resource Limited Settings.

M. Hughes, R. Gross, J. Mellors, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Discordance between Etravirine Phenotype and Genotype-Based Predicted Phenotype for Subtype C HIV-1 from First-Line Antiretroviral Therapy Failures in South Africa

P. Harrigan, J. Mellors, K. McCormick, 2020, Antimicrobial Agents and Chemotherapy.

Failure of Initial Therapy With Two Nucleosides and Efavirenz Is Not Associated With Early Emergence of Mutations in the C-Terminus of HIV-1 Reverse Transcriptase

M. Hughes, R. Haubrich, J. Mellors, 2011, Journal of acquired immune deficiency syndromes.

Long-acting antiretrovirals and HIV treatment adherence.

J. Nachega, J. Mellors, L. Mofenson, 2023, The lancet. HIV.

Obesity Modifies the Relationship Between Raltegravir and Dolutegravir Hair Concentrations and Body Weight Gain in Women Living with HIV.

A. Adimora, J. Mellors, F. Palella, 2023, AIDS research and human retroviruses.

Single-dose nevirapine to prevent mother-to-child transmission of HIV type 1: balancing the benefits and risks.

J. Mellors, Jeremy Y Chow, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Arteriolization of venous blood gases: a clue to the diagnosis of cyanide poisoning.

J. Mellors, J. Mellors, R. P. Johnson, 1988, The Journal of emergency medicine.

Clinical characteristics and natural history of patients with acute myocardial infarction sent home from the emergency room.

G W Rouan, M. Weisberg, J. Mellors, 1987, The American journal of cardiology.

Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size

Daniel I. S. Rosenbloom, R. Ptak, D. Richman, 2020, The Journal of Infectious Diseases.

Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers

J. Mellors, G. Shaw, R. Ribeiro, 2016, PLoS pathogens.

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206

J. Phair, Tanmoy Bhattacharya, Steven Wolinsky, 2010, AIDS.

The largest HIV-1-infected T cell clones in children on long-term combination antiretroviral therapy contain solo LTRs

S. Hughes, J. Mellors, G. V. Van Zyl, 2023, mBio.

Global HIV control: is the glass half empty or half full?

J. Nachega, T. Quinn, J. Mellors, 2023, The lancet. HIV.

Frequency of Antiretroviral Resistance Mutations among Infants Exposed to Single-Dose Nevirapine and Short Course Maternal Antiretroviral Regimens: ACTG A5207

J. Mellors, U. Lalloo, J. Pape, 2014, Journal of AIDS & clinical research.

Single-cell analysis reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of ovarian cancer

J. Mellors, H. Osmanbeyoglu, S. Cascio, 2023, bioRxiv.

A computer protocol to predict myocardial infarction in emergency department patients with chest pain.

E F Cook, L Goldman, Karen M. Daley, 1988, The New England journal of medicine.

A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.

J. Mellors, J. Currier, A. Landay, 2012, The Journal of infectious diseases.

Antiretroviral Drug Resistance Testing in Adult Hiv-1 Infection: 2008 Recommendations of an International Aids Society–usa Panel

S. Hammer, D. Richman, V. Johnson, 2022 .

Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial.

M. Reitsma, J. Mellors, R. Kantor, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy

R. Stephens, J. Lifson, J. Mellors, 2009, Retrovirology.

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.

H. Günthard, J. Schapiro, J. Mellors, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection

C. Loveday, J. Mellors, L. Demeter, 2000 .

Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.

M. Hughes, R. Schooley, J. Mellors, 2014, The Journal of infectious diseases.

Tumor necrosis factor-alpha/cachectin enhances human immunodeficiency virus type 1 replication in primary macrophages.

J. Mellors, J. Mellors, J. Ryan, 1991, The Journal of infectious diseases.

Altered in vivo activity of liposome-incorporated lipopolysaccharide and lipid A

J. Mellors, J. Dijkstra, J. Mellors, 1989, Infection and immunity.

No evidence of HIV replication in children on antiretroviral therapy.

J. Mellors, B. Luke, J. Coffin, 2017, The Journal of clinical investigation.

Subphenotypes of self-reported symptoms and outcomes in long COVID: a prospective cohort study with latent class analysis

J. Mellors, F. Sciurba, C. Kessinger, 2023, BMJ Open.

A phase I/II randomized, placebo-controlled trial of romidepsin in persons with HIV-1 on suppressive antiretroviral therapy to assess safety and activation of HIV-1 expression (A5315).

J. Karn, J. Mellors, E. Acosta, 2020, The Journal of infectious diseases.

Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.

R. Glaubius, U. Abbas, J. Mellors, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

J. Mellors, C. K. Chu, N. Ilksoy, 1993, Antimicrobial Agents and Chemotherapy.

Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals after First-Line Antiretroviral Therapy Failure in South Africa

J. Mellors, P. Harrigan, C. Brumme, 2016, Antimicrobial Agents and Chemotherapy.

HIV-1 Continues To Replicate and Evolve in Patients with Natural Control of HIV Infection

J. Mellors, J. Coffin, F. Maldarelli, 2010, Journal of Virology.

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment

R. Haubrich, D. Havlir, J. Mellors, 2009, AIDS.

Pre-exposure prophylaxis (PrEP) will have a limited impact on the prevalence of HIV-1 drug resistance in sub-Saharan Africa: comparison of mathematical models

R. Glaubius, K. Lythgoe, J. Eaton, 2012 .

Dendritic cells focus CTL responses toward highly conserved and topologically important HIV-1 epitopes.

B. Korber, J. Ananworanich, J. Mellors, 2021, EBioMedicine.

No evidence that circulating HIV-specific immune responses contribute to persistent inflammation and immune activation in persons on long-term ART

J. Mellors, R. Bosch, R. B. Jones, 2022, AIDS.